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We have identi®ed and isolated ectopically expressed
tyrosinase transcripts in normal human melanocytes
and lymphocytes and in a human melanoma
(MNT-1) cell line to establish a baseline for the
expression pattern of this gene in normal tissue.
Tyrosinase mRNA from human lymphoblastoid cell
lines was reverse transcribed and ampli®ed using
speci®c ``nested'' primers. This ampli®cation yielded
eight identi®able transcripts; ®ve that resulted from
alternative splicing patterns arising from the utiliza-
tion of normal and alternative splice sequences.
Identical splicing patterns were found in transcripts
from human primary melanocytes in culture and a
melanoma cell line, indicating that lymphoblastoid
cell lines provide an accurate re¯ection of transcript
processing in melanocytes. Similar splicing patterns
have also been found with murine melanocyte tyrosi-
nase transcripts. Our results demonstrate that alter-
native splicing of human tyrosinase gene transcript
produces a number of predictable and identi®able
transcripts, and that human lymphoblastoid cell lines
provide a source of ectopically expressed transcripts
that can be used to study the biology of tyrosinase
gene expression in humans. Key words: ectopic expres-
sion/lymphoblastoid cell line/lymphocyte/melanocyte/spli-
cing/tyrosinase. J Invest Dermatol 117:1261±1265, 2001
T
yrosinase (monophenol oxidase, EC1.14.18.1) is a
copper-containing enzyme critical to the formation of
melanin in the melanosome within the melanocyte
(Lerner and Fitzpatrick, 1950). Its major function is to
catalyze the hydroxylation of tyrosine to dopaquinone
(Cooksey et al, 1997). Dopaquinone then forms red±yellow
pheomelanin or black±brown eumelanin depending primarily on
the availability of sulfhydryl compounds (Prota, 1980). Tyrosinase
functions as part of an enzyme±protein complex within the
melanosome and is not active in vivo before vesicular transport to
this organelle (Orlow et al, 1994). Mutations that inactivate this
enzyme reduce the amount of melanin synthesized in the
melanocyte and produce oculocutaneous albinism (OCA) in mice
and humans (Shibahara et al, 1988, 1990; Spritz et al, 1990; Oetting
2000).
The murine and human tyrosinase genes have a similar structure,
with ®ve exons that encode a protein with a putative leader
sequence, two copper-binding domains, and a trans-membrane
domain (MuÈller et al, 1988; Ruppert et al, 1988; Giebel et al, 1991).
The predominant expression of the murine gene is a full-length
mRNA but multiple smaller mRNA are produced (MuÈller et al,
1988; Terao et al, 1989; Porter and Mintz, 1991). The smaller
mRNA arise from alternative splicing, and do not produce active
enzyme (Porter and Mintz, 1991; Terao et al, 1989). Recent studies
have also demonstrated alternative splicing in the gene for
tyrosinase-related-protein 2/dopachrome tautomerase, another
member of the tyrosinase gene family (Pawelek et al, 1980;
Pisarra et al, 2000). Most of the studies of alternative splicing of
the murine tyrosinase or the tyrosinase-related-protein 2 gene were
performed with melanoma tissue.
We now report our analysis of alternative splicing of the normal
human tyrosinase gene. These studies were undertaken to provide
information on the biology of this gene and to further our
understanding of human OCA resulting from mutations of this
gene (OCA1). To overcome the dif®culty in obtaining large
numbers of melanocytes from normal and affected individuals, a
method for analyzing ectopic transcription of the tyrosinase gene in
cultured lymphoblastoid cell lines derived from peripheral blood
lymphocytes was developed.
MATERIALS AND METHODS
Cell lines and cultures Lymphocytes were isolated from heparinized
whole blood from normally pigmented individuals using a Ficoll gradient
(Histopaque, Sigma, St Louis, MO). The isolated lymphocytes were
transformed using Epstein±Barr Virus (EBV) and cyclosporine to establish
lymphoblastoid cell lines (Pelloquin et al, 1986). Normal human primary
melanocytes in culture were kindly provided by Raymond Boissy, PhD,
Department of Dermatology, University of Cincinnati, OH. A human
melanoma cell line, MNT-1, was kindly provided by Vincent Hearing,
PhD, NIH and was maintained in Dulbecco's minimal Eagle's medium
culture media (Sigma) under standard culture conditions.
RNA extraction and reverse transcription Total RNA from
lymphoblastoid cell lines was isolated using a protocol modi®ed from
Glisen and Ullrich (Sambrook et al, 1989). Reverse transcription was
performed using 10±15 mg total RNA, 20 pmol tyrosinase speci®c
primers, 20 units of RNasin (Promega, Madison, WI), 200 units of
reverse transcriptase with 1 3 reverse transcription buffer (Gibco,
Rockville, MD), 0.5 mM of each deoxyribonucleoside triphosphate and
0.01 M dithiothreitol (the ®nal reaction volume was 20 ml). The reaction
was incubated at 42°C for 2 h and terminated by heating at 70°C for
15 min. Complementary RNA strands were then removed by the
addition of 2 units of RNase H (Gibco) and incubating at 37°C for
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20 min. In all cases DEPC treated sterile water was added in place of
RNA as a negative control.
Polymerase chain reaction (PCR) ampli®cation The cDNA is
ampli®ed twice using a series of nested primer sets that allowed
ampli®cation of speci®c regions of the tyrosinase gene (NCBI accession
number 0000372). The locations of the primers are shown in Fig 1 and
the primer sequences are given in Table I.
For ampli®cation, the entire reverse transcription reaction was mixed
with 1.5 mM MgCl2, 1 3 PCR buffer (Cetus, Norwalk, CT), 0.2 mM
of each deoxyribonucleoside triphosphate, 5 units of Taq Polymerase
(Cetus) and 20 pmol of each forward and reverse ampli®cation primer
for the region to be ampli®ed. The ampli®cation reactions were
performed with 40 cycles using standard protocols. The reaction was
then ®ltered through a 30,000 NMWL spin ®lter (Millipore, Bedford,
MA) to separate the excess ampli®cation primers prior to the second
ampli®cation. The second ampli®cation reaction conditions were the
same with the exception that a nested set of primers were utilized, and
10% of the ®rst round reaction was used as template. The negative
reverse transcription control was used in the negative control reaction.
Ampli®ed products were cloned into a TA vector (Invitrogen, Carlsbad,
CA) for the isolation of individual products (Clark, 1988; Mead et al,
1991).
Analysis of reverse transcription±PCR products The products of
the second round of ampli®cation were separated and visualized by
electrophoresis of 10 ml sample in 1.2% agarose containing ethidium
bromide.
The ampli®cation products were sequenced using either ¯uorescent
sequencing primers or primers end-labeled with 32P-adenosine tripho-
sphate. Reaction conditions for both methods were the same. Prior to
sequencing, the ampli®cation reactions were ®ltered through a 30,000
NMWL ®lter to remove excess PCR primers. Samples were cycle-
sequenced as previously described (Oetting et al, 1994). The isotopically
labeled sequence reactions were electrophoresed on a 60 cm acrylamide
gel (8%) containing 8 M urea and 1 3 trio-boric acid EDTA buffer.
The sequencing ladder was visualized using autoradiography. The ¯uor-
escent labeled sequence reactions were separated on a 33 cm acrylamide
gel (8%) containing 8 M urea and 1 3 TBE buffer on a LI-COR
Systems S-4000 autosequencer (LI-COR Inc, Lincoln, NE) (Oetting
et al, 1994).
RESULTS
Initial studies showed that adequate amounts of tyrosinase mRNA
were available for PCR ampli®cation from lymphoblastoid cell
lines, and that tyrosinase cDNA could be readily visualized with
ethidium bromide and sequenced. To establish that the cDNA
represented products of both tyrosinase alleles of an individual, the
reverse transcription±PCR product of mRNA from a normally
pigmented individual who was heterozygous at the codon 192
polymorphism (Y192S; TCT/TAT) in exon 1 of the tyrosinase
gene was analyzed (Giebel et al, 1991; Oetting et al, 1993). The
Y192S mutation represents a common polymorphism with equal
frequencies of the two alleles in the Caucasian population. As
shown in Fig 2, the cDNA sequence clearly showed both
tyrosinase alleles for codon 192, indicating that the transcript
from both alleles was ectopically expressed in a lymphoblastoid cell
line.
Lymphoblastoid cell line RNA from six normally pigmented
individuals was used to identify transcripts of the normal tyrosinase
gene. Three regions of the tyrosinase cDNA were ampli®ed using
the primers in Table I. Ampli®cation of these regions with cDNA
from lymphoblastoid cell line mRNA produced products of the
expected size (N1-3), as shown in Fig 3(A) for one individual. Five
smaller products were also identi®ed, and each was cloned into a
TA vector, sequenced and compared with the known tyrosinase
cDNA sequence (Mead et al, 1991). Repeat analysis of reverse
transcription±PCR products did not consistently demonstrate all
smaller products from each of the six individuals, but each product
could be identi®ed with transcript-speci®c primers (Table II) in
cDNA from all six individuals (data not shown). The ®ve smaller
transcripts resulted from alternative splicing, using three alternative
splice sites in exon 1 and the normal 3¢ and 5¢ splice sites of exon 3.
The alternatively spliced transcripts were more readily identi®ed
by further ampli®cation using transcript-speci®c primers (Figs 3B
and 4). The design of these primers was based on the sequence of
the alternative splice junctions of transcripts A±E, such that the
primers would span the splice site junctions. The 5¢ and 3¢ ends of
the primers were on opposite sides of the splice junction, and they
would anneal only to the cDNA of the speci®cally spliced
transcripts and not to the normal cDNA sequences. A transcript-
speci®c primer was used with either primer F2 (transcript A), R2
(transcript C), or R6 (transcripts B, D, and E) to amplify the
alternative spliced cDNA, illustrated in Fig 4. In transcript A, an
alternative donor splice site in codon 118 and an alternative
acceptor splice site at codon 266 generated a transcript of 384 bp.
In transcript B, an alternative donor splice site in codon 53 and the
normal exon 2 acceptor splice site generated a transcript of 534 bp.
In transcript C, the codon 118 alternative donor splice site and the
normal exon 2 acceptor splice site were used to generate a transcript
of 211 bp. In transcript D, exon 3 was spliced out using the normal
donor and acceptor splice sites, and this generated a transcript of
171 bp. In transcript E, the codon 53 alternative donor splice site
and the normal exon 4 acceptor splice site were used to generate a
transcript of 167 bp.
Figure 1. Primer location. Primers used in reverse transcription and
ampli®cation of speci®c transcript regions are shown in relation to the
®ve exons of the human tyrosinase gene. The locations of the forward
(above) and reverse primers (below) are indicated.
Table I. Ampli®cation primer sequences
5¢ forward primers
F1 5¢-ACT CCA ATT AGC CAG TTC C-3¢,
F2 5¢-TTG TGA GGA CTA GAG GAA GA-3¢
F3 5¢-ATG GAT GCA CTG CTT GGG GGA-3¢
F4 5¢-ATT GTC TGT AGC CGA TTG GAÐ3¢
F5 5¢-TGG AAC GCC CGA GGG ACC TT-3¢
3¢ reverse primers
R1 5¢-CTT CCA GTG TAT TTC TAA AGC-3¢
R2 5¢-TCT AAA GCT GAA ATT GGC AGC-3¢
R3 5¢-CTG TCA ACA AAT GCA TGG TG-3¢
R4 5¢-GAA GGA AGA TAG GAT CGT T-3¢
R5 5¢-CTG AAT CTT GTA GAT AGC TA-3¢
R6 5¢-AGT CAT AGC CCA GAT CTT TG-3¢
R7 5¢-GGT GCA TTG GCT TCT GGA TA-3¢
Figure 2. Tyrosinase gene sequence adjacent to codon 192
polymorphism. Ampli®cation and sequencing of genomic DNA from
an individual demonstrated heterozygosity at codon 192 (TCT/TAT).
Lymphoblastoid cell line reverse transcription±PCR product from the
same individual was sequenced for the codon 192 region, showing that
both alleles are expressed in lymphoblastoid cell lines.
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The alternative splicing at codons 53, 118, and 266 appears to
result from the presence of cryptic splice sites at these locations, as
shown in Figs 5 and 6. Consensus donor splice site sequences
(AG|gtragt) are found at codons 53 and 118 (Reed and Maniatis,
1985). A consensus acceptor splice site and the upstream branch
point (YNYTRAY¼¼. (Y)nNYAG) are found with codon 266.
Thus, the alternative splicing that we have identi®ed involved
cryptic splice sites that exist in the tyrosinase gene sequence.
RNA from normal human primary melanocyte cultures was used
to con®rm that the splicing observed in lymphoblastoid cell line
mRNA was representative of the pigment cell and not an artifact of
ectopic expression. Normal melanocyte RNA was reverse tran-
scribed using tyrosinase-speci®c primers (R2 and R5) and ampli®ed
Table II. Sequences for transcript-speci®c primers (TSP)
TSP-A 5¢-AAG AAT GAT GCA AGA GTC GT-3¢
TSP-B 5¢-TCA GGC AGA GAT TGT CTG TA-3¢
TSP-C 5¢-ACG ACT CTT ATT GTC TGT AG-3¢
TSP-D 5¢-ACA CTG GAA GTA TTT TTG AG-3¢
TSP-E 5¢-TCA GGC AGA GTA TTT TTG AG-3¢
Figure 4. Location of transcript speci®c primers. Approximate
location of 5¢ and 3¢ sequences of transcript-speci®c junction primers in
relation to the ®ve exons of the tyrosinase gene are indicated by the
stippled half-boxes shown paired with the respective ampli®cation
primer. The solid lines indicate the regions that were ampli®ed and the
dotted lines indicate the regions of the mRNA that have been removed
by alternative splicing.
Figure 5. Three cryptic splice sites are identi®ed in the tyrosinase
gene coding region. The consensus splice site sequences, the normal
splice sites of the tyrosinase gene, and the sequences adjacent to codons
53, 118, and 266 of the tyrosinase gene are shown. The branch point of
the 3¢ splice sites are underlined.
Figure 3. Identi®cation of transcripts. (A) Ampli®cation of three
tyrosinase gene regions with cDNA from a single individual. M: 1 kb
molecular marker. N1±N3: normal transcripts of reverse transcription±
PCR reactions with primers F2±R2 (N1, 5¢ UTR through exon 2); F2±
R4 (N2, 5¢ UTR through exon 3); and F2±R6 (N3, 5¢ UTR through
exon 4). Smaller individual transcripts were subsequently identi®ed on
repeat gels, cloned into a TA vector and used for sequence analysis to
identify their origin. (B) Ampli®cation with transcript-speci®c primers.
M: 100 bp molecular marker. Normal transcripts: N1±N3 as in (A).
Alternative transcripts and size: (A) 384 bp; (B) 534 bp; (C) 211 bp; (D)
171 bp; and (E) 167 bp.
Figure 6. Diagram showing normal and alternatively spliced
tyrosinase transcripts identi®ed from human lymphoblastoid
RNA. Sequence N represents the normal sequence showing the 5 exons
of the tyrosinase gene. (A±E) Represent alternatively spliced transcripts.
The mRNA regions removed by alternative splicing are indicated by the
stippled regions. Cryptic splice sites are located at codons 53, 118, and
266.
Figure 7. Alternatively spliced transcripts in normal melanocyte
RNA. Normal melanocyte total RNA was reverse transcribed and
tyrosinase sequences were ampli®ed using the transcript-speci®c primer
pairs. The alternatively spliced transcripts (A±E), identi®ed in
lymphoblastoid cell line RNA, were also found in normal melanocytes
by ampli®cation of the speci®c transcripts using transcript-speci®c primer
pairs. The bands re¯ect the expected sizes of the alternatively spliced
transcripts. Lane M represents 100 bp ladder. (A) 384 bp; (B) 534 bp;
(C) 211 bp; (D) 171 bp; and (E) 167 bp.
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using transcript-speci®c primers (Table II). This analysis showed a
single ampli®ed product of the expected size for each alternatively
spliced transcript, as shown in Fig 7. All alternatively spliced
transcripts found in lymphoblastoid cell lines were readily identi®ed
in normal melanocyte RNA, showing that this processing is not the
result of ectopic expression or aberrant processing in the trans-
formed lymphocytes.
DISCUSSION
Melanin forms in the melanocyte, a specialized cell found in the
skin, hair follicle, eye, and ear. Tyrosinase is the key enzyme in the
formation of melanin by catalyzing the initial step in melanin
synthesis, which is necessary for the subsequent formation of both
black±brown eumelanin and red±yellow pheomelanin (Lerner and
Fitzpatrick, 1950; Prota, 1980). Mutations of the tyrosinase gene
are associated with partially or totally inactive enzyme, and reduced
melanin in the melanocyte. The loss of melanin produces the
clinical phenotype known as OCA.
Human OCA is complex, with at least seven different gene loci
being involved (King et al, 1995; Dell'Angelica et al, 1999;
Shotelersuk et al, 2000). Mutations of the tyrosinase gene produ-
cing OCA1 are usually identi®ed by sequence analysis of the coding
region of the gene with DNA from affected individuals. The
majority are missense mutations. One large tyrosinase gene deletion
has been identi®ed as well as several nonsense, frameshift, and
splice-site mutations (Oetting and King, 1999; Schnur et al, 1996;
Matsunaga et al, 1999; Oetting, 2000). There are, however, a
number of individuals with an OCA1 phenotype (i.e., white hair,
white skin, and blue eyes) who do not have two identi®able
mutations in the coding region of the gene, and it is hypothesized
that some of these individuals have mutations that affect the
transcription of the gene or processing of the transcription product
(Oetting, 2000; Gilhar et al, 1995). Studies of melanocytes would
provide an approach to analyzing tyrosinase transcription products,
but melanocytes are generally not available from these individuals.
To overcome these problems, we have developed a method that
will allow us to analyze ectopic tyrosinase gene transcription
products in lymphoblastoid cell lines from individuals with
albinism. A similar approach has been used successfully in other
genetic diseases (Bidichandani et al, 1995; Tavassoli et al, 1997;
Kure et al, 1998; Ars et al, 2000; Tassone et al, 2000).
There were two critical points to address in establishing the
utility of this approach. First, the transcript pattern for the
tyrosinase gene had to be established. We readily identi®ed
transcripts of this gene in lymphoblastoid cell lines. In addition to
the normal-sized transcripts, we identi®ed ®ve smaller transcripts
resulting from variant splicing that removed different regions or
exons of the gene from the transcript through the use of normal or
alternative splice sites. These transcripts are presumably degraded
rather than processed in these cells as there is no evidence that they
are involved in melanin synthesis. Similar transcript variants of the
tyrosinase gene have been identi®ed in mouse skin melanocytes and
melanoma, and these transcripts do not result in active tyrosinase
protein (Porter et al, 1991; MuÈller et al, 1988; Ruppert et al, 1988;
Le Fur et al, 1996; Kelsall et al, 1997). In the mouse, exon 1
contains two alternative donor splice sites (at bp 291 and 369) and
two alternative receptor splice sites (at bp 522 and 858); the normal
splice site at the 3¢ end of exon 1 is at bp 881 (Kelsall et al, 1997).
The locations of the alternative splice sites in the mouse are similar
to but not identical to those that produce alternative transcripts in
human lymphoblastoid cell line mRNA.
Second, the reliability of the transcript pattern in lymphoblastoid
cell lines had to be determined by comparing this with the pattern
in human melanocytes. Normal melanocytes in primary culture and
a human melanoma cell line (MNT1) were found to produce the
same pattern of tyrosinase gene transcripts (Figs 6 and 7) indicating
that the lymphoblastoid cell lines could be a surrogate for tyrosinase
gene transcript analysis when melanocytes are not available.
An additional point is raised with these studies. The detection of
tyrosinase mRNA in peripheral blood has been suggested as a
method for monitoring the clinical course of patients with
melanoma (Smith et al, 1991; Alao et al, 1999; Calogero et al,
2000; Johansson et al, 2000a, b; Kulik et al, 2001). Studies have
described the extraction of mRNA from peripheral blood mono-
nuclear or buffy coat cells, suggesting that circulating melanoma
cells may be present. Our results indicate that the presence of
ectopic tyrosinase gene transcripts may arise from lymphocytes in
the blood cells obtained for the analysis, rather than from
circulating melanoma cells. This may explain why this diagnostic
approach for melanoma has proven to be problematic (Calogero
et al, 2000; Aubin et al, 2000; Tsao et al, 2001).
These studies provide the ®rst description of the use of ectopic
transcription analysis with the human tyrosinase gene. We have also
identi®ed transcripts of the P gene in lymphoblastoid cell lines (data
not shown); the product of this gene is involved in melanin
biosynthesis and mutations of the gene are associated with OCA2
(Gardner et al, 1992; Lee et al, 1995; Oetting et al, 1998). This
approach to transcript analysis may be useful when the primary
transcript of a gene is not available because of the lack of access to
the critical tissue. Future studies of human disorders of pigmen-
tation resulting from mutations affecting splicing or transcription of
the tyrosinase gene should be possible using this approach.
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